Geron Corporation (GERN) stock forecast & analysis
0.8944
NasdaqGS · USDDelayed by 15 minutes
Down: -0.0518, -5.5%
0.8901Down: -0.0043, -0.5%
1 analysis
Latest analysis: · verdict locked
- Open
- 0.9300
- Previous close
- 0.9462
- Day range
- 0.8606 – 0.9373
- 52-week range
- 0.8400 – 2.01
- Volume (shares)
- 18.80M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 642.47M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 0.61
- Market cap
- 574.63M
Market Scanner’s AI analysis of Geron Corporation (GERN), updated October 2026: Geron's stock price decline follows imetelstat trial discontinuation, with mixed financial and technical signals.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Geron Corporation (GERN) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Geron's stock price decline follows imetelstat trial discontinuation, with mixed financial and technical signals.
Recent analyses for Geron Corporation (GERN) covered a significant stock price downturn following the discontinuation of its Phase 3 imetelstat trial for myelofibrosis. The market analyst report detailed bearish technical indicators and oversold conditions, while the fundamentals analyst noted revenue growth alongside negative profit margins and cash flow. The news analyst highlighted the trial halt and subsequent analyst price target adjustments, alongside commentary on the Rytelo business.
GERN news & sentiment
Negative news flow dominated recent coverage following the discontinuation of a key clinical trial, leading to a notable stock price decline. Social media discussion was not covered in the provided notes.
GERN technical picture
Geron's stock price has experienced a significant downturn, trading below its 50-day and 200-day SMAs, signaling weakness in medium-term and long-term trends. Momentum indicators suggest bearish sentiment, with the RSI and MFI in oversold territory and the MACD below zero, while the price is also below the lower Bollinger Band.
Fundamentals
Geron reported year-over-year revenue growth alongside negative profit and operating margins. The company maintained strong short-term liquidity with substantial cash reserves relative to its debt and negative free cash flow.
Factors discussed — upside
- Quarterly revenue growth of 17.2% year-over-year.
- Strong short-term liquidity with a current ratio of 6.915.
- Significant cash reserves of $300.85 million against $122.14 million in debt.
- Rytelo business remains on track according to some analyst commentary.
Factors discussed — risks
- Discontinuation of Phase 3 imetelstat trial for myelofibrosis.
- Significant stock price decline over 7, 30, and 91-day periods.
- Price trading below 50-day and 200-day SMAs, indicating bearish trends.
- Negative profit and operating margins.
- Negative free cash flow for the year ending December 31, 2025.
- Clinical trial outcomes
- Technical indicators
- Financial performance
- Liquidity and cash flow
Summary updated .
GERN technical indicators
Common technical indicators for GERN, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 1.29 | Price below |
| 10-day exponential moving average | 1.06 | Price below |
| Relative strength index (14-day) | 22.13 | Oversold |
| MACD line (12/26/9) | -0.0823 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 0.96 – 1.35 | Price below the lower band |
Analyses
Recent GERN.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-29 GERN.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Geron Corporation?
- The bull case for Geron Corporation centers on its revenue growth and strong liquidity position, supported by substantial cash reserves and a robust current ratio. Additionally, commentary suggests the company's core Rytelo business remains on track despite other setbacks.
- What are the risks for Geron Corporation?
- Risks for Geron Corporation include the discontinuation of its Phase 3 imetelstat trial, which has contributed to a significant stock price decline and bearish technical indicators. The company also faces headwinds from negative profit margins and a history of negative free cash flow.
- Is Geron Corporation bullish or bearish?
- Recent AI analyses of Geron Corporation examined factors on both sides. Discussed upside: The bull case for Geron Corporation centers on its revenue growth and strong liquidity position, supported by substantial cash reserves and a robust current ratio. Additionally, commentary suggests the company's core Rytelo business remains on track despite other setbacks. Discussed risks: Risks for Geron Corporation include the discontinuation of its Phase 3 imetelstat trial, which has contributed to a significant stock price decline and bearish technical indicators. The company also faces headwinds from negative profit margins and a history of negative free cash flow. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Geron Corporation?
- Negative news flow dominated recent coverage following the discontinuation of a key clinical trial, leading to a notable stock price decline. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Geron Corporation?
- Every analysis of Geron Corporation runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Geron Corporation?
The bull case for Geron Corporation centers on its revenue growth and strong liquidity position, supported by substantial cash reserves and a robust current ratio. Additionally, commentary suggests the company's core Rytelo business remains on track despite other setbacks.
What are the risks for Geron Corporation?
Risks for Geron Corporation include the discontinuation of its Phase 3 imetelstat trial, which has contributed to a significant stock price decline and bearish technical indicators. The company also faces headwinds from negative profit margins and a history of negative free cash flow.
Is Geron Corporation bullish or bearish?
Recent AI analyses of Geron Corporation examined factors on both sides. Discussed upside: The bull case for Geron Corporation centers on its revenue growth and strong liquidity position, supported by substantial cash reserves and a robust current ratio. Additionally, commentary suggests the company's core Rytelo business remains on track despite other setbacks. Discussed risks: Risks for Geron Corporation include the discontinuation of its Phase 3 imetelstat trial, which has contributed to a significant stock price decline and bearish technical indicators. The company also faces headwinds from negative profit margins and a history of negative free cash flow. These are descriptive observations, not a recommendation.
What is the latest sentiment on Geron Corporation?
Negative news flow dominated recent coverage following the discontinuation of a key clinical trial, leading to a notable stock price decline. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse Geron Corporation?
Every analysis of Geron Corporation runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh GERN.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.